Key result
In vitro administration of 4-factor prothrombin complex concentrates at a dose of 25 U/kg was sufficient to restore normal thrombin generation in plasma from rivaroxaban-treated patients.
Why the study?
PCC supports rivaroxaban reversal but might increase thrombotic events by shifting the haemostatic balance towards hypercoagulability.
Does in vitro administration of 4-factor PCC improve thrombin generation in blood samples from patients treated with rivaroxaban?
Does in vitro administration of 4-factor PCC improve thrombin generation in blood samples from patients treated with rivaroxaban?
In vitro analysis suggests that a lower dose of 25 U/kg of 4-factor PCC may be sufficient to reverse the anticoagulant effect of rivaroxaban, potentially minimizing thrombotic risk compared to the standard 50 U/kg dose.
Answers are grounded in this paper and cite their sources.
In vitro data should not change PCC dosing practice; hypothesis-generating for optimized reversal in future clinical studies.
Rivaroxaban has the most available data to support the use of prothrombin complex concentrates (PCC) as a reversal agent. However, PCC might increase the incidence of thrombotic events by shifting the haemostatic balance towards hypercoagulability. We assessed the in vitro efficacy and safety of three 4-factor PCCs for reversing rivaroxaban anticoagulant effect. Our in vitro finding indicates that 4-factor PCCs at the dose of 25 U.kg − 1 may be sufficient to reverse rivaroxaban anticoagulant effect.
No takes yet. Share an insight, caveat, or question.
Giffard-Quillon et al. (2020) conducted a letter in Venous thromboembolism treated with rivaroxaban (n=40). 4-factor prothrombin complex concentrates (PCC) vs. Unspiked plasma (baseline) was evaluated on Thrombin generation peak height (nM). In vitro administration of 4-factor prothrombin complex concentrates at a dose of 25 U/kg was sufficient to restore normal thrombin generation in plasma from rivaroxaban-treated patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: